News Brief: Eli Lilly Obesity Pill Shows Promise for Weight Maintenance
Summary
Eli Lilly announced positive late-stage trial results for its experimental daily obesity pill, orforglipron. The data shows the pill effectively helped patients maintain most of their weight loss after switching from popular injectable drugs like Wegovy and Zepbound. The company has filed for FDA approval.
Key Points
- Effective Maintenance: Patients switching from Wegovy maintained ~95% of lost weight; those from Zepbound maintained ~80% over 52 weeks on the pill.
- FDA Submission: Lilly has filed for FDA approval of orforglipron. The drug has a priority review voucher, potentially expediting the decision.
- Market Dynamics: The pill offers a convenient, needle-free option for long-term weight maintenance. However, Novo Nordisk’s oral version of Wegovy is expected to reach the market first.
- Financial Potential: Analysts project significant sales, with one firm forecasting $16 billion in revenue for Lilly’s pill by 2028.
- Safety & Pricing: Side effects were primarily mild-to-moderate gastrointestinal issues. Pricing is unclear, but a direct-to-consumer channel may offer it at $149/month starting January.
- Mechanism: It’s a non-peptide GLP-1 drug, meaning easier absorption and no strict dietary restrictions compared to some rivals.
新闻简报：礼来减肥药在患者从Wegovy和Zepbound转换后显示出维持减重效果
摘要
礼来公司公布了其实验性每日口服减肥药orforglipron的积极后期试验结果。数据显示，在患者从Wegovy和Zepbound等流行注射药物转换后，该药片能有效帮助其维持大部分减重效果。公司已向美国FDA提交上市申请。
关键点
- 有效维持体重：从Wegovy转换过来的患者在服药52周后维持了约95%的减重；从Zepbound转换的患者维持了约80%。
- 提交FDA审批：礼来已向FDA提交orforglipron的上市申请。该药拥有优先审评凭证，可能加快审批流程。
- 市场动态：该药片为长期体重维持提供了方便的无针选择。然而，诺和诺德的口服版Wegovy预计将率先上市。
- 财务潜力：分析师预测其销售额潜力巨大，有机构预计到2028年该药年销售额可达160亿美元。
- 安全性与定价：副作用主要是轻度至中度的胃肠道问题。定价尚不明确，但一个直接面向消费者的渠道可能从1月起以每月149美元的价格提供。
- 作用机制：它是一种非肽类GLP-1药物，意味着比某些竞品更容易吸收，且无需严格的饮食限制。
Original Article Link: https://www.cnbc.com/2025/12/18/eli-lilly-obesity-pill-maintains-weight-loss-after-wegovy-zepbound-.html